相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prediction of response to tapentadol in chronic low back pain
M. Reimer et al.
EUROPEAN JOURNAL OF PAIN (2017)
Efficacy and Safety of Tapentadol Immediate Release Assessment in Treatment of Moderate to Severe Pain: A Systematic Review and Meta-Analysis
Jing-Ping Xiao et al.
PAIN MEDICINE (2017)
Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats
Vijay Benade et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers
R. van der Schrier et al.
BRITISH JOURNAL OF ANAESTHESIA (2017)
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study
Alain Serrie et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Is tapentadol different from classical opioids? A review of the evidence
Richard M. Langford et al.
BRITISH JOURNAL OF PAIN (2016)
A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy
Sherwyn Schwartz et al.
CLINICAL DRUG INVESTIGATION (2015)
The Mu-Opioid Receptor Agonist/Noradrenaline Reuptake Inhibition (MOR-NRI) Concept in Analgesia: The Case of Tapentadol
Thomas M. Tzschentke et al.
CNS DRUGS (2014)
On subclasses of opioid analgesics
Robert B. Raffa
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit
A. Cowan et al.
EUROPEAN JOURNAL OF PAIN (2014)
Computational Methods in Drug Discovery
Gregory Sliwoski et al.
PHARMACOLOGICAL REVIEWS (2014)
Bowel Function After Tapentadol and Oxycodone Immediate Release (IR) Treatment in Patients With Low Back or Osteoarthritis Pain
Winghan J. Kwong et al.
CLINICAL JOURNAL OF PAIN (2013)
Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain
Keiichiro Imanaka et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Mu Opioids and Their Receptors: Evolution of a Concept
Gavril W. Pasternak et al.
PHARMACOLOGICAL REVIEWS (2013)
Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study
Ilona Steigerwald et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Mechanistic and functional differentiation of tapentadol and tramadol
Robert B. Raffa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Current Considerations for the Treatment of Severe Chronic Pain: The Potential for Tapentadol
Joseph Pergolizzi et al.
PAIN PRACTICE (2012)
Chronic pain - moving from symptom control to mechanism-based treatment
Joseph Pergolizzi
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Systematic review of tapentadol in chronic severe pain
Rob Riemsma et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Synergistic Interaction between the Two Mechanisms of Action of Tapentadol in Analgesia
W. Schroeder et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Antinociceptive and Antihyperalgesic Effects of Tapentadol in Animal Models of Inflammatory Pain
Klaus Schiene et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Efficacy and Safety of Tapentadol Prolonged Release for Chronic Osteoarthritis Pain and Low Back Pain
Bernd Lange et al.
ADVANCES IN THERAPY (2010)
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study
Marc Afilalo et al.
CLINICAL DRUG INVESTIGATION (2010)
On deriving the dose-effect relation of an unknown second component: An example using buprenorphine preclinical data
Ronald J. Tallarida et al.
DRUG AND ALCOHOL DEPENDENCE (2010)
Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?
Hans G. Kress
EUROPEAN JOURNAL OF PAIN (2010)
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain
Wolfgang Schroeder et al.
EUROPEAN JOURNAL OF PAIN (2010)
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study
Robert Buynak et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs
Ye Hu et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2010)
Central modulation of pain
Michael H. Ossipov et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
IN VITRO AND IN VIVO CHARACTERIZATION OF TAPENTADOL METABOLITES
R. Terlinden et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2010)
Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain
Thomas Christoph et al.
NEUROSCIENCE LETTERS (2010)
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain
James E. Wild et al.
PAIN PRACTICE (2010)
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine
Zhe Ding et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study
Craig Hartrick et al.
CLINICAL THERAPEUTICS (2009)
Tapentadol Hydrochloride: A Centrally Acting Oral Analgesic
William E. Wade et al.
CLINICAL THERAPEUTICS (2009)
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain
Stephen E. Daniels et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study
Martin Hale et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery
Jens-Ulrich Stegmann et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Neuropathic pain: multiple mechanisms at multiple sites
Lucy A. Bee et al.
FUTURE NEUROLOGY (2007)
(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl):: a novel μ-opioid receptor agonist norepinephrine Reuptake inhibitor with broad-spectrum analgesic properties
Thomas M. Tzschentke et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts
Grant R. Zimmermann et al.
DRUG DISCOVERY TODAY (2007)
Tapentadol hydrochloride. Analgesic, Mu-opioid receptor agonist, noradrenaline reuptake inhibitor.
T. M. Tzschentke et al.
DRUGS OF THE FUTURE (2006)
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites
Bojan Lalovic et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Buprenorphine induces ceiling in respiratory depression but not in analgesia
A Dahan et al.
BRITISH JOURNAL OF ANAESTHESIA (2006)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Historical review: Opioid receptors
SH Snyder et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2003)
分享论文
